Re: ERT/HRT- personal prescribing trend

From: Joanne Bulley, MD (islesannie@yahoo.com)
Sun Oct 20 11:14:21 2002


I agree - I have been convinced it wasn't the estrogen - but MANY medical people - providers of care, cancer surgeons, etc have been very vocal on the estrogen = breast cancer commentaries. And that is a hard line to counter - even when there is good data.

Thanks for the article refernce.

Joanne

At Sun, 20 Oct 2002, Dr. Abdelhamid Attia wrote: >
>No! It is not the estrogen.
>
>A study done by Shairer et al., 2000 analyzing the follow-up data of 46,355 postmenopausal women found a 1% (0.01) yearly increase in the RR of developing a breast cancer in estrogen only users versus an 8% (0.08) yearly increase in RR in estrogen+progetin users. This means that after 5 years of use there would be a 5% and 40% increase in the RR of breast cancer in ERT versus HRT users (RR 1.05 & 1.4 respectively).
>
>So, it may be the progestin added or a combined effect that leads to the increased incidence of breast cancer.
>
>Shairer et al. Menopausal Estrogen and Estrogen-Progestin Replacement Therapy and Breast Cancer Risk. JAMA 2000; 283:485-491
>
>--
>Abdelhamid Attia
>

--
Joanne Bulley, MD
Keene, NH, USA




use when must restrict search to only the ob-gyn-l forum...
Enter search keywords:
Returns per screen: Require all keywords:

Return to  OB-GYN-L Mail a New Message to the Forum: ob-gyn-l@obgyn.net
Forum Administrator: geffrey.klein@obgyn.net
Report Technical Problems: webmaster@obgyn.net
Last Updated: Wed Dec 2 04:54:14 2009

The American Medical Association is no longer designating CME hours for AMA Category II CME credit. However, physicians themselves may self designate learning activities as Category II CME credit hours if they feel it is of sufficient educational merit and meets the formal definitions of continuing medical education. OBGYN.net believes these interaction in this forum meets these criteria. For further information see the AMA web site.